CD8A and neoplasm: While the number of AH1-specific CD8+ T cells was slightly but non-significantly decreased in BCG and BCG in combination with anti-PD-1 ICI-treated tumors when compared with the mock group, PeptiBAC-AH1 in combination with anti-PD-1 ICI-treated tumors had significantly increased numbers of AH1-specific CD8+ T cells, suggesting a correlation between tumor growth control and the number of AH1-specific CD8+ T cells in the TME (figure 6B, upper panel).